[144] Takeda Pharmaceutical Company Limited American SEC Filing

Rhea-AI Filing Summary

This Form 144 filing indicates that an unidentified holder of Takeda Pharmaceutical Company Limited (TAK) American Depositary Shares (ADSs) plans to sell up to 5,608 ADSs through Interactive Brokers on or about 9 July 2025 on the NYSE. The block is valued at roughly $86,475 based on the market price reported in the form. The shares derive from restricted-stock-unit awards that vested on 1 July 2025. With 123.49 million ADSs outstanding, the proposed sale represents only about 0.0045 % of the float, implying immaterial dilution or trading-volume impact. No other sales have been made by the filer in the past three months, and the signer certifies the absence of undisclosed adverse information. While insider sales occasionally raise sentiment concerns, the size and routine compensation origin suggest limited market significance.

Positive

• Sale equals only ~0.0045 % of Takeda’s outstanding ADSs, indicating negligible dilution or trading impact.

Negative

• Insider disposition, even if small, can signal profit-taking and may be perceived negatively by some investors.

Insights

Securities Analyst

TL;DR: Small Form 144 insider sale (≈$86k) from vested RSUs; immaterial at 0.0045 % of shares—neutral for TAK investors.

The filing discloses a routine disposition of 5,608 ADSs originating from recently vested equity compensation. Transaction value is modest relative to Takeda’s multi-billion-dollar market capitalization and the 123 million ADS float. No pattern of ongoing selling is evident, and the filer reports no other sales in the prior quarter. Therefore, liquidity or control implications are negligible. From a sentiment standpoint, any insider sale can be read cautiously, yet the scale and compensation source reduce concern. I classify the news as neutral/not impactful for the investment thesis.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
American Depositary Shares (ADSs)	Interactive Brokers LLC One Pickwick Plaza Greenwich CT 06830	5608	86475.36	123490548	07/09/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
ADSs	07/01/2025	Restricted Stock Unit Awards - Vested.	Takeda Pharmaceutical Company Limited			12032	07/01/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many Takeda (TAK) ADSs are being sold under this Form 144?

The notice covers up to 5,608 American Depositary Shares.

What is the estimated market value of the proposed TAK share sale?

The aggregate market value reported is approximately $86,475.

When is the anticipated sale date for the TAK ADSs?

The filer lists an approximate sale date of 9 July 2025.

What percentage of Takeda’s total ADSs does the sale represent?

It equals roughly 0.0045 % of the 123.49 million ADSs outstanding.

Where will the TAK ADSs be sold and through which broker?

They are to be sold on the NYSE via Interactive Brokers LLC.

What is the origin of the shares being sold?

The ADSs were received from restricted-stock-unit awards that vested on 1 July 2025.